A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin

PHASE3RecruitingINTERVENTIONAL

Enrollment

620

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

February 7, 2026

Study Completion Date

February 28, 2026

Conditions

Diabetes

Interventions

DRUG

GZR4

GZR4 s.c., once-weekly，treat-to-target dose

DRUG

insulin degludec

insulin degludec s.c.,once-daily，treat-to-target dose

Trial Locations (1)

RECRUITING

Gan & Lee Pharmaceuticals Shandong Co., Ltd., Linyi